Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting
A third presentation shows that intratumoral vaccination with nanoparticles incorporating tumor antigen peptides and a TLR9 agonist provides anti-tumor immunity superior to conventional subcutaneous vaccination. Direct intratumoral vaccination using this novel vaccine platform and mode of administration significantly increases both the magnitude and functional activity of vaccine-primed cytotoxic T lymphocytes (CTL) and enhances control of metastatic disease.
The details of the poster presentations are as follows:
Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)
|Location:||Poster section 34; Board number 5|
Development of an inhaled TLR9 agonist for the immunotherapy of lung cancer
|Location:||Poster section 30; Board number 12|
Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration
|Location:||Poster section 24; Board number 28|
For information about SD-101 trials that are currently recruiting patients, please visit www.clinicaltrials.gov.
This press release contains "forward-looking" statements, including expectations for the conduct and timing of clinical trials of SD-101, and other investigational compounds. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether we can timely provide adequate clinical supplies; initiation, enrollment and completion of clinical trials of SD-101; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; the ability to successfully develop and commercialize SD-101; and whether or not
KEYTRUDA® is a registered trademark of
News Provided by Acquire Media